key: cord-0707824-ue09khtb authors: Sobelman, Celia S.; Valentine, Stacey L.; Kremer, Ted title: Management of COVID-19 in an adolescent demonstrates lasting effects of extreme prematurity on pulmonary function date: 2021-03-19 journal: Respir Med Case Rep DOI: 10.1016/j.rmcr.2021.101394 sha: bcccc5fe77f3d82f8c707d02f8ec807e0ba8fd65 doc_id: 707824 cord_uid: ue09khtb Extremely premature infants have demonstrated increased survival due to advancements in care. This population is at risk for decreased lung function that persists into adolescence. It is important for clinicians to consider this history when treating and assessing such patients who contract SARS-CoV-2 respiratory infection. A 17-year-old, former premature infant of 23 weeks gestation with BPD presented to the pediatric emergency department for evaluation of hypoxia and increased work of breathing in the setting of SARS-CoV-2 infection. He was managed aggressively with early noninvasive respiratory support, Remdesevir, systemic steroids, and convalescent plasma. Utilization of aggressive medical therapies early in the hospital course assisted in preventing intubation and mechanical ventilation for this patient. While there are studies examining the severity of SARS-CoV-2 infection in premature infants, there is a paucity of data on this vulnerable group as they age into adolescence. More studies are needed to assess the severity of illness and optimal management of this population. Article Summary: 26 A former 23-week gestation infant, now an adolescent, contracted SARS-CoV-2 infection, 27 representing an emerging population that should be considered in the current pandemic . 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 Introduction: 50 Advances in neonatology have increased the survival of extremely premature infants, and infants with 51 bronchopulmonary dysplasia (BPD). 1 These infants have reduced lung function into their adolescent 52 years, with a known decline in function that persists into adulthood 2,3 making this vulnerable 53 population one that can be significantly affected in the COVID-19 pandemic. There are few studies 54 examining the outcomes of former extremely premature infants with SARS-CoV-2 respiratory 55 infection, who have the potential to become seriously ill with respiratory infections. 4 The following 56 case is a 17-year-old who was born at 23 weeks gestation and presented with hypoxia and respiratory 57 distress due to SARS-CoV-2 infection. This case serves as a reminder to providers that prematurity and 58 BPD are important historical risk factors in assessing the severity of respiratory infections including 59 the current pandemic, even into adolescence. The use of noninvasive respiratory support helped bridge 60 the patient to recovery as his medical treatment began to take effect. His medical management was 61 adapted from adult protocols, and represents a promising outcome for adolescents. 62 63 Case Summary: 64 A 17-year-old Hispanic male with asthma, prematurity born at 23 weeks, BPD, and autism was 65 admitted to the pediatric intensive care unit due to acute hypoxic respiratory failure in the setting of 66 SARS-CoV-2 associated pneumonia. His father was a positive contact and was admitted to the medical 67 ICU prior to this patient's admission. The patient tested positive for SARS-CoV-2 PCR eight days 68 prior to his admission. At that time the patient had developed isolated fevers with a peak temperature 69 of 39.9°C, but was otherwise asymptomatic. His home management included acetaminophen, and 70 combination acetaminophen, dextromethorphan and phenylephrine. Six days after his positive test, he 71 presented to the pediatric emergency department (PED) for shortness of breath. At that time, he did not 72 have hypoxia, but did have laboratory criteria consistent with acute SARS-CoV-2 infection: 73 lymphopenia and elevated c-reactive protein, in addition to a known positive PCR test. He had a chest 74 x-ray at that time which showed mild bronchial wall thickening. He was otherwise medically stable 75 and was discharged home. He returned to the PED two days later presenting with fever and hypoxia, 76 room air O2 saturations of 90%. His chest x-ray was notable for low lung volumes with bibasilar 77 opacities. Laboratory abnormalities included an elevated lactic acid of 4.84 mmol/L, elevated c-78 reactive protein of 41.6 mg/L, and lymphopenia to absolute count of 0.9 x 10 3 /uL. D-dimer, brain 79 natriuretic peptide, troponin I, prothrombin time, partial prothrombin time and international 80 normalized ratio were all normal. In the emergency department inhaled albuterol and ipratropium were 81 delivered for symptomatic relief with no effect. The patient was admitted on respiratory support of 82 three liters per minute oxygen via nasal cannula, but due to increased work of breathing, was quickly 83 escalated to high-flow nasal cannula (HFNC) oxygen at 20 liters per minute with 40% FiO2, and 84 subsequently escalated to biphasic positive pressure ventilation (BiPAP) (maximum settings RR 16, 85 IPAP 12, EPAP 6, FiO2 0.6) using full face mask. On admission he received a 200mg loading dose of 86 Remdesevir, which he continued at a dose of 100mg daily for five days. On hospital day one he 87 received his first dose of convalescent plasma, and received daily for a total of six doses during his 88 admission. He was also started on dexamethasone 6 mg daily for a ten-day course, or until hospital 89 discharge. He was compliant with awake prone positioning for more than 12 hours daily. On hospital 90 day three he weaned from BiPAP to HFNC and on hospital day six he was transitioned to low flow 91 nasal cannula oxygen. On hospital day seven he weaned to room air, and on hospital day eight he was 92 discharged home with no O2 requirement. 93 with SARS-CoV-2. 5 In this patient, it is less likely that asthma played a significant role in the severity 100 of his illness. Typical asthma treatments did not improve the patient's symptoms, and there is 101 conflicting evidence on whether childhood asthma is truly a risk factor for development of severe 102 respiratory disease in SARS-CoV-2. Although respiratory viruses are a common trigger of asthma 103 exacerbations, similarly to this case, SARS-CoV-2 does not seem to trigger asthma exacerbations. In 104 fact, it is suggested that, paradoxically, allergic asthma is a protective measure against severe disease 105 due to potential under-expression of angiotensin-converting enzyme 2 (ACE2) receptor, which is 106 Vital Capacity (FVC) ratio at 69%. His FEV1 was 89% predicted. It is logical to consider that as these 120 infants grow and develop, they are likely at a higher risk of severe complications from SARS-CoV-2 121 due to the known reduction in their respiratory function. 122 Management of this patient's illness is notable for prone positioning, noninvasive respiratory support, 123 and medical therapy. Although there is a risk of aerosolization with noninvasive respiratory support, 124 this risk may be reduced by using lower pressures and a closed circuit. In this patient's case, a closed 125 circuit was not utilized, however, a viral filter was placed over the exhalation port of the high-flow and 126 BiPAP units. Additionally, the highest flow the patient received during his admission was 40 liters per 127 minute; below the limit set by the institution of 50 liters per minute. Young adults with a similar 128 history should be identified and clinicians should have a low threshold for PICU admission, as this 129 population has the potential to decompensate quickly and require more advanced forms of respiratory 130 support. This population may represent a group that benefits greatly with aggressive medical 131 therapies. This patient received three key medical therapies to improve his respiratory status; a 132 systemic steroid (dexamethasone), an antiviral medication (Remdesevir), and the study treatment 133 convalescent plasma from patients who had previously recovered from SARS-COV-2 infection. 134 Recent studies have shown convalescent plasma increases neutralizing antibody titers and reduces 135 overall mortality in critically ill patients. 9 The use of remdesevir in pediatric patients has increased, as 136 more children are presenting with severe disease 10 . In many cases the medication is used with 137 improved clinical outcome and minimal side effects, in the short term. 11 The use of dexamethasone is a 138 known treatment for adults with SARS-CoV-2 infection that reduces mortality in patients with severe 139 disease. 12 Although the safety and efficacy of use of steroids in Pediatric patients infected with SARS-140 CoV-2is not known, it is considered a reasonable therapy in children with more severe disease. As more former premature infants age into adolescence and young adulthood during the current 148 pandemic, an emphasis on historical factors is key to identify those who are at risk for respiratory 149 decompensation. More studies are needed to compare former premature infants with BPD in their 150 adolescent years to their full-term counterparts who developed SARS-CoV-2 infection and respiratory 151 illness. This sentinel case serves as a reminder that BPD may be a risk factor for severe disease. 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 J o u r n a l P r e -p r o o f Trends in Care Practices, Morbidity, and Mortality of 194 Extremely Preterm Neonates Pulmonary outcome 197 in adolescents of extreme preterm birth: a regional cohort study Longitudinal follow-up of lung function from childhood to adolescence in prematurely born 201 patients with neonatal chronic lung disease BPD Following Preterm Birth: A Model for Chronic Lung 204 Disease and a Substrate for ARDS in Childhood United States Centers for Disease Control and Prevention. People with certain medical 207 conditions COVID-19 in children with underlying chronic 210 respiratory diseases: survey results from 174 centres COVID-19-related Genes in Sputum Cells in Asthma. 213 Relationship to Demographic Features and Corticosteroids [published correction appears in Am 214 J Respir Crit Care Med Preterm birth: Potential risk factor for greater COVID-19 217 severity? 219 Convalescent plasma transfusion for the treatment of COVID-19: Systematic review ACTT-1 Study Group Members. Remdesivir for the Treatment 227 of Covid-19 -Final Report Compassionate use of 230 remdesivir in children with COVID-19 Diaz 235 G, Subramanian A; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients 236 with Severe Covid-19 Institute of Health. COVID-19 Treatment Guidelines: Corticosteroids. Available at 239 Dexamethasone in Hospitalized 245 Patients with Covid-19 -Preliminary Report